Payment overview · 2025
General Payments
$208.74
6 reported records · 4 companies
Healthcare provider profile · identity verified
Gloriane Afonso-Fede, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DARTMOUTH, MA · NPI 1376525063
Verified facts
What the public records show
CMS Open Payments records show Gloriane Afonso-Fede, M.D. received $208.74 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 62.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.49 | 62.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.85 | 21.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.05 | 9.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.35 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.74 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $130.49 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 696 | 206 |
| Omeprazole | Omeprazole | 521 | 166 |
| Pravastatin Sodium | Pravastatin Sodium | 487 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 468 | 146 |
| Lisinopril | Lisinopril | 467 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 104 |
| Losartan Potassium | Losartan Potassium | 354 | 112 |
| Metformin Hcl | Metformin Hcl | 345 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 90 |
| Gabapentin | Gabapentin | 283 | 66 |
| Simvastatin | Simvastatin | 283 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 256 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 242 | 110 |
| Lovastatin | Lovastatin | 222 | 74 |
| Sertraline Hcl | Sertraline Hcl | 191 | 49 |
| Furosemide | Furosemide | 187 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 61 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 47 |
| Metformin Hcl Er | Metformin Hcl | 140 | 50 |
| Ezetimibe | Ezetimibe | 133 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 35 |
| Eliquis | Apixaban | 124 | 23 |
| Famotidine | Famotidine | 122 | 41 |
| Montelukast Sodium | Montelukast Sodium | 121 | 36 |
| Nystatin | Nystatin | 119 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 30 |
| Ketoconazole | Ketoconazole | 105 | 38 |
| Enalapril Maleate | Enalapril Maleate | 91 | 26 |
| Mirtazapine | Mirtazapine | 78 | 24 |
| Prednisone | Prednisone | 77 | 60 |
| Tramadol Hcl | Tramadol Hcl | 76 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 39 |
| Januvia | Sitagliptin Phosphate | 73 | 17 |
| Glimepiride | Glimepiride | 72 | 27 |
| Valsartan | Valsartan | 69 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 69 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Trazodone Hcl | Trazodone Hcl | 65 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 20 |
| Celecoxib | Celecoxib | 60 | 29 |
| Methylprednisolone | Methylprednisolone | 60 | 58 |
| Meclizine Hcl | Meclizine Hcl | 58 | 29 |
| Farxiga | Dapagliflozin Propanediol | 57 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 19 |
| Alprazolam | Alprazolam | 52 | 16 |
| Hydrocortisone | Hydrocortisone | 51 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Glipizide | Glipizide | 43 | 11 |
| Mupirocin | Mupirocin | 42 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Meloxicam | Meloxicam | 39 | 12 |
| Azelastine Hcl | Azelastine Hcl | 37 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 35 |
| Atenolol | Atenolol | 36 | 11 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 11 |
| Cefuroxime | Cefuroxime Axetil | 34 | 31 |
| Metronidazole | Metronidazole | 34 | 17 |
| Potassium Chloride | Potassium Chloride | 34 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Benzonatate | Benzonatate | 20 | 15 |
| Estradiol | Estradiol | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 13 | 11 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.74 · 6 records | Lilly USA, LLC | AIRSUPRA, Cologuard Collection Kit, KISUNLA, NURTEC ODT, The Cologuard Plus Collection Kit, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error